FDA approves Teva’s monthly schizophrenia injection
The U.S. Food and Drug Administration has approved WELTRUZA, a long-acting, once-monthly injectable antipsychotic from Teva for adults with schizophrenia. The drug delivers olanzapine gradually under the skin over about a month, aiming to reduce the need for daily medications and frequent clinic visits.
What changed: new monthly injection approved
The FDA greenlit WELTRUZA as a monthly, long-acting form of olanzapine, designed to be given as a single subcutaneous injection. It is intended for adults with schizophrenia and is presented as an option when continuous symptom control is needed with less frequent dosing.
Who it affects
Adults diagnosed with schizophrenia who may benefit from reduced dosing frequency could consider this treatment. The approval is for adults, and use in younger people or other conditions would require separate evaluation. The drug is delivered by a healthcare professional in a clinic or similar setting, not by patients at home.
Practical next steps
If a patient or caregiver is considering this option, the next steps are to discuss with a psychiatrist or prescribing clinician whether monthly olanzapine injections fit their treatment plan. Healthcare providers will review medical history, potential side effects, and how the monthly injection compares to daily tablets or other long-acting formulations. Regular follow-up appointments are still expected to monitor effectiveness and safety. Patients should report any concerning symptoms, including excessive drowsiness, movement disorders, weight changes, or metabolic effects.
Limits and questions to ask your clinician
Key points to clarify include: how the monthly injection compares with existing long-acting choices, what monitoring is required after the injection, potential side effects specific to olanzapine (such as weight gain, metabolic changes, sleepiness). How injection timing might affect mood or behavior. It’s also important to confirm insurance coverage, out-of-pocket costs, and who administers the injection at which location.
Which sources did Setup in Bahrain review?
Setup in Bahrain reviewed the following source material before preparing this explanatory article.
The links remain visible so readers can inspect the evidence, compare dates and context, and confirm current requirements with the relevant authority.
- israelnationalnews.com — evidence source reviewed for this article.
Information and responsibility notice: This article is general information based on the cited material available when published. It is not legal, tax, immigration, medical, financial, banking, or investment advice; it does not create a professional-client relationship; and it is not a guarantee of outcome, availability, accuracy, or eligibility. Rules, schedules, prices, and third-party information can change. Confirm material decisions with the relevant authority and an appropriately qualified adviser before acting.